The Asia-Pacific stem cell market is estimated to develop with a CAGR of 9.16% over the forecasted period of 2022 to 2030, acquiring a revenue share of $4441.37 million by 2030.

ASIA-PACIFIC STEM CELL MARKET FORECAST 2022-2030

Asia-Pacific Stem Cell Market by Therapeutic Application (Orthopedic Treatments, Injuries & Wounds, Oncology Disorders, Cardiovascular Disorders, Neurological Disorders, Diabetes, Other Therapeutic Applications) Market by Product (Adult Stem Cell, Human Embryonic Stem Cell, Pluripotent, Mouse/Rat Neural) Market by Technology (Cell Acquisition, Cell Production, Cryopreservation, Expansion & Sub-culture) By Geography

Request free sample

The Asia-Pacific stem cell market is estimated to develop with a CAGR of 9.16% over the forecasted period of 2022 to 2030, acquiring a revenue share of $4441.37 million by 2030.

The rising medical tourism in emerging countries such as India and China, collaborations between Asian governments, international health agencies, as well as private firms, and significant investments in medical research and healthcare facilities are primarily attributed to the market growth of the region. However, the Asia-Pacific stem cell market may face challenges such as the absence of a structured finance arrangement, ethical issues involved in stem cell research, and complications associated with the preservation of stem cells.

Asia-Pacific Stem Cell Market

To know more about this report, request a free sample copy

The Asia-Pacific stem cell market growth evaluation constitutes the assessment of China, Japan, India, Australia & New Zealand, South Korea, Thailand, Indonesia, Vietnam, and Rest of Asia Pacific. The market for stem cells is augmenting in China, with the significant growth attributable to the increasing involvement of the government in strengthening the nation’s biotech industry. Aligning with this, the Government of China, in 2019, dedicated $18 billion to biotechnology research in its latest five-year plan. The presence of a supportive regulatory framework for stem cell research, growing private and public initiatives to reinforce the use of stem cell treatment, and the expansion and modernization of healthcare infrastructure further fuel the stem cell market growth in China.

On the other hand, researchers in Japan have significantly contributed to stem cell therapies over the years. The country’s research involvement is primarily attributed to the importance of stem cells in terms of treating incurable diseases. Japan is also anticipated to be one of the most lucrative regions in the stem cell market, with a core focus on induced pluripotent stem cells, which hold tremendous potential in the field of regenerative medicine.

Furthermore, in 2022, Japan-Metcela acquired Japan Regenerative Medicine Co Ltd, a wholly owned subsidiary of Kidswell Bio Co Ltd, to add to its pipeline an autologous cell product for pediatric congenital heart disease. This factor will greatly strengthen the industry’s clinical development infrastructure for regenerative medicine products. Hence, these drivers are set to propel the stem cell market growth in the Asia-Pacific during the forecast period.

The Asia-Pacific stem cell market is segmented into therapeutic application, product, technology, application, and treatment type. The technology segment entails cell acquisition, cell production, expansion & sub-culture, and cryopreservation. Stem cell acquisition entails the process of procuring stem cells from mature tissues like peripheral blood, bone marrow, and umbilical cord blood through bone marrow harvesting, umbilical cord stem cell acquisition, and apheresis.

Stem cells, post-acquisition, are cryopreserved or stored frozen in liquid nitrogen at temperatures below -140 degrees Celsius. Moreover, preservants such as DMSO, as well as tiny tubes termed cryovials, are utilized for this purpose.

Some of the top players in the Asia-Pacific stem cell market include Becton, Dickinson and Company, Qiagen NV, Takara Holdings Inc, etc.

Takara Holdings Inc, headquartered in Japan, is a biotechnology company. Its business is segmented into gene therapy, bio-industry, and agri-bio. The company’s products are used globally for regenerative medicine research and evaluation of candidate substances of medicines.

Report Synopsis

Report Scope Details
Market Forecast Years 2022-2030
Base Year 2021
Market Historical Years 2018-2021
Forecast Units Revenue ($ Million)
Segments Analyzed Therapeutic Application, Product, Technology, Application, Treatment Type
Countries Analyzed China, Japan, India, Australia & New Zealand, South Korea, Thailand, Indonesia, Vietnam, and Rest of Asia Pacific
Companies Analyzed

AllCells LLC, Becton, Dickinson and Company, Corning Inc, Lorem Cytori Inc, GE Healthcare, International Stem Cell Corporation (ISCO), Merck KGaA (Sigma Aldrich), Miltenyi Biotec, Pluri Inc, Qiagen, Smith+Nephew PLC, Stemcell Technologies Inc, Stryker Corporation, Takara Holdings Inc, Thermo Fisher Scientific Inc

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • KEY DRIVERS
        • SURGING DEMAND FOR STEM CELLS IN REGENERATIVE MEDICINE
        • GROWING R&D INVESTMENTS IN STEM CELL THERAPIES & RESEARCH
        • RISING AWARENESS ABOUT UMBILICAL CORD STEM CELLS
        • REDUCED RISK OF TISSUE REJECTION IN TRANSPLANTS
      • KEY RESTRAINTS
        • ABSENCE OF A WELL-DEFINED REGULATORY FRAMEWORK FOR STEM CELL THERAPY
        • HIGH COSTS ASSOCIATED WITH STEM CELL PROCEDURES
        • ETHICAL ISSUES AND SOCIAL COMPLEXITIES
        • LESS RESPONSIVENESS IN DEVELOPED ECONOMIES
    1. KEY ANALYTICS
      • IMPACT OF COVID-19 ON STEM CELL MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • VALUE CHAIN ANALYSIS
      • KEY BUYING CRITERIA
        • PRICE
        • EFFICACY
        • APPLICATION AND EFFECTIVENESS
        • ACCURACY
      • REGULATORY FRAMEWORK
    2. MARKET BY THERAPEUTIC APPLICATION
      • ORTHOPEDIC TREATMENTS
      • INJURIES & WOUNDS
      • ONCOLOGY DISORDERS
      • CARDIOVASCULAR DISORDERS
      • NEUROLOGICAL DISORDERS
      • DIABETES
      • OTHER THERAPEUTIC APPLICATIONS
    3. MARKET BY PRODUCT
      • ADULT STEM CELL
        • HEMATOPOIETIC STEM CELL
        • NEURAL STEM CELL
        • UMBILICAL CORD STEM CELL
        • MESENCHYMAL STEM CELL
        • DENTAL STEM CELL
      • HUMAN EMBRYONIC STEM CELL
      • PLURIPOTENT
      • MOUSE/RAT NEURAL
    4. MARKET BY TECHNOLOGY
      • CELL ACQUISITION
        • BONE MARROW HARVEST
        • UMBILICAL CORD
        • APHERESIS
      • CELL PRODUCTION
        • THERAPEUTIC CLONING
        • IN VITRO FERTILIZATION (IVF)
        • CELL CULTURE
        • ISOLATION
      • CRYOPRESERVATION
      • EXPANSION & SUB-CULTURE
    5. MARKET BY APPLICATION
      • REGENERATIVE MEDICINE
      • DRUG DISCOVERY AND DEVELOPMENT
    6. MARKET BY TREATMENT TYPE
      • ALLOGENEIC STEM CELL THERAPY
      • AUTOLOGIC STEM CELL THERAPY
      • SYNGENEIC STEM CELL THERAPY
    7. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • MARKET ESTIMATES & SIZES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • CHINA
          • JAPAN
          • INDIA
          • AUSTRALIA & NEW ZEALAND
          • SOUTH KOREA
          • THAILAND
          • INDONESIA
          • VIETNAM
          • REST OF ASIA-PACIFIC
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • ACQUISITIONS
        • PARTNERSHIPS
      • COMPANY PROFILES
        • ALLCELLS LLC
        • BECTON, DICKINSON AND COMPANY (BD)
        • CORNING INC
        • LOREM CYTORI INC
        • GE HEALTHCARE
        • INTERNATIONAL STEM CELL CORPORATION
        • MERCK KGAA (SIGMA ALDRICH)
        • MILTENYI BIOTEC
        • PLURI INC
        • QIAGEN
        • SMITH+NEPHEW PLC
        • STEMCELL TECHNOLOGIES INC
        • STRYKER CORPORATION
        • TAKARA HOLDINGS INC
        • THERMO FISHER SCIENTIFIC INC

    LIST OF TABLES

    TABLE 1: ASIA-PACIFIC MARKET SNAPSHOT – STEM CELL

    TABLE 2: EXAMPLES OF APPROVED CELL THERAPY PRODUCTS

    TABLE 3: REGULATORY FRAMEWORK

    TABLE 4: ASIA-PACIFIC STEM CELL MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 5: ASIA-PACIFIC STEM CELL MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 6: ASIA-PACIFIC STEM CELL MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 7: ASIA-PACIFIC STEM CELL MARKET, BY PRODUCT, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 8: ASIA-PACIFIC STEM CELL MARKET, BY ADULT STEM CELL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 9: ASIA-PACIFIC STEM CELL MARKET, BY ADULT STEM CELL, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 10: ASIA-PACIFIC STEM CELL MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 11: ASIA-PACIFIC STEM CELL MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 12: ASIA-PACIFIC STEM CELL MARKET, BY CELL ACQUISITION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 13: ASIA-PACIFIC STEM CELL MARKET, BY CELL ACQUISITION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 14: ASIA-PACIFIC STEM CELL MARKET, BY CELL PRODUCTION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 15: ASIA-PACIFIC STEM CELL MARKET, BY CELL PRODUCTION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 16: ASIA-PACIFIC STEM CELL MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 17: ASIA-PACIFIC STEM CELL MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 18: ASIA-PACIFIC STEM CELL MARKET, BY TREATMENT TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 19: ASIA-PACIFIC STEM CELL MARKET, BY TREATMENT TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 20: ASIA-PACIFIC STEM CELL MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 21: ASIA-PACIFIC STEM CELL MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 22: LEADING PLAYERS OPERATING IN ASIA-PACIFIC STEM CELL MARKET

    TABLE 23: LIST OF ACQUISITIONS

    TABLE 24: LIST OF PARTNERSHIPS   

    LIST OF FIGURES

    FIGURE 1: KEY MARKET TRENDS

    FIGURE 2: STEM CELL SCREENING STRATEGIES AND THEIR POTENTIAL APPLICATION

    FIGURE 3: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 4: OPPORTUNITY MATRIX

    FIGURE 5: VENDOR LANDSCAPE

    FIGURE 6: VALUE CHAIN ANALYSIS

    FIGURE 7: KEY BUYING CRITERIA

    FIGURE 8: ASIA-PACIFIC STEM CELL MARKET, GROWTH POTENTIAL, BY THERAPEUTIC APPLICATION, IN 2021

    FIGURE 9: ASIA-PACIFIC STEM CELL MARKET, BY ORTHOPEDIC TREATMENTS, 2022-2030 (IN $ MILLION)

    FIGURE 10: ASIA-PACIFIC STEM CELL MARKET, BY INJURIES & WOUNDS, 2022-2030 (IN $ MILLION)

    FIGURE 11: ASIA-PACIFIC STEM CELL MARKET, BY ONCOLOGY DISORDERS, 2022-2030 (IN $ MILLION)

    FIGURE 12: ASIA-PACIFIC STEM CELL MARKET, BY CARDIOVASCULAR DISORDERS, 2022-2030 (IN $ MILLION)

    FIGURE 13: ASIA-PACIFIC STEM CELL MARKET, BY NEUROLOGICAL DISORDERS, 2022-2030 (IN $ MILLION)

    FIGURE 14: ASIA-PACIFIC STEM CELL MARKET, BY DIABETES, 2022-2030 (IN $ MILLION)

    FIGURE 15: ASIA-PACIFIC STEM CELL MARKET, BY OTHER THERAPEUTIC APPLICATIONS, 2022-2030 (IN $ MILLION)

    FIGURE 16: ASIA-PACIFIC STEM CELL MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021

    FIGURE 17: ASIA-PACIFIC STEM CELL MARKET, BY ADULT STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 18: ASIA-PACIFIC STEM CELL MARKET, GROWTH POTENTIAL, BY ADULT STEM CELL, IN 2021

    FIGURE 19: ASIA-PACIFIC STEM CELL MARKET, BY HEMATOPOIETIC STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 20: ASIA-PACIFIC STEM CELL MARKET, BY NEURAL STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 21: ASIA-PACIFIC STEM CELL MARKET, BY UMBILICAL CORD STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 22: ASIA-PACIFIC STEM CELL MARKET, BY MESENCHYMAL STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 23: ASIA-PACIFIC STEM CELL MARKET, BY DENTAL STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 24: ASIA-PACIFIC STEM CELL MARKET, BY HUMAN EMBRYONIC STEM CELL, 2022-2030 (IN $ MILLION)

    FIGURE 25: ASIA-PACIFIC STEM CELL MARKET, BY PLURIPOTENT, 2022-2030 (IN $ MILLION)

    FIGURE 26: ASIA-PACIFIC STEM CELL MARKET, BY MOUSE/RAT NEURAL, 2022-2030 (IN $ MILLION)

    FIGURE 27: ASIA-PACIFIC STEM CELL MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021

    FIGURE 28: ASIA-PACIFIC STEM CELL MARKET, BY CELL ACQUISITION, 2022-2030 (IN $ MILLION)

    FIGURE 29: ASIA-PACIFIC STEM CELL MARKET, GROWTH POTENTIAL, BY CELL ACQUISITION, IN 2021

    FIGURE 30: ASIA-PACIFIC STEM CELL MARKET, BY BONE MARROW HARVEST, 2022-2030 (IN $ MILLION)

    FIGURE 31: ASIA-PACIFIC STEM CELL MARKET, BY UMBILICAL CORD, 2022-2030 (IN $ MILLION)

    FIGURE 32: ASIA-PACIFIC STEM CELL MARKET, BY APHERESIS, 2022-2030 (IN $ MILLION)

    FIGURE 33: ASIA-PACIFIC STEM CELL MARKET, BY CELL PRODUCTION, 2022-2030 (IN $ MILLION)

    FIGURE 34: ASIA-PACIFIC STEM CELL MARKET, GROWTH POTENTIAL, BY CELL PRODUCTION, IN 2021

    FIGURE 35: ASIA-PACIFIC STEM CELL MARKET, BY THERAPEUTIC CLONING, 2022-2030 (IN $ MILLION)

    FIGURE 36: ASIA-PACIFIC STEM CELL MARKET, BY IN VITRO FERTILIZATION (IVF), 2022-2030 (IN $ MILLION)

    FIGURE 37: ASIA-PACIFIC STEM CELL MARKET, BY CELL CULTURE, 2022-2030 (IN $ MILLION)

    FIGURE 38: ASIA-PACIFIC STEM CELL MARKET, BY ISOLATION, 2022-2030 (IN $ MILLION)

    FIGURE 39: ASIA-PACIFIC STEM CELL MARKET, BY CRYOPRESERVATION, 2022-2030 (IN $ MILLION)

    FIGURE 40: ASIA-PACIFIC STEM CELL MARKET, BY EXPANSION & SUB-CULTURE, 2022-2030 (IN $ MILLION)

    FIGURE 41: ASIA-PACIFIC STEM CELL MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

    FIGURE 42: ASIA-PACIFIC STEM CELL MARKET, BY REGENERATIVE MEDICINE, 2022-2030 (IN $ MILLION)

    FIGURE 43: ASIA-PACIFIC STEM CELL MARKET, BY DRUG DISCOVERY AND DEVELOPMENT, 2022-2030 (IN $ MILLION)

    FIGURE 44: ASIA-PACIFIC STEM CELL MARKET, GROWTH POTENTIAL, BY TREATMENT TYPE, IN 2021

    FIGURE 45: ASIA-PACIFIC STEM CELL MARKET, BY ALLOGENEIC STEM CELL THERAPY, 2022-2030 (IN $ MILLION)

    FIGURE 46: ASIA-PACIFIC STEM CELL MARKET, BY AUTOLOGIC STEM CELL THERAPY, 2022-2030 (IN $ MILLION)

    FIGURE 47: ASIA-PACIFIC STEM CELL MARKET, BY SYNGENEIC STEM CELL THERAPY, 2022-2030 (IN $ MILLION)

    FIGURE 48: ASIA-PACIFIC STEM CELL MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN%)

    FIGURE 49: CHINA STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 50: JAPAN STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 51: INDIA STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 52: AUSTRALIA & NEW ZEALAND STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 53: SOUTH KOREA STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 54: THAILAND STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 55: INDONESIA STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 56: VIETNAM STEM CELL MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 57: REST OF ASIA-PACIFIC STEM CELL MARKET, 2022-2030 (IN $ MILLION)       

    1. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • MARKET ESTIMATES & SIZES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • CHINA
          • JAPAN
          • INDIA
          • AUSTRALIA & NEW ZEALAND
          • SOUTH KOREA
          • THAILAND
          • INDONESIA
          • VIETNAM
          • REST OF ASIA-PACIFIC
    1. MARKET BY THERAPEUTIC APPLICATION
      • ORTHOPEDIC TREATMENTS
      • INJURIES & WOUNDS
      • ONCOLOGY DISORDERS
      • CARDIOVASCULAR DISORDERS
      • NEUROLOGICAL DISORDERS
      • DIABETES
      • OTHER THERAPEUTIC APPLICATIONS
    2. MARKET BY PRODUCT
      • ADULT STEM CELL
        • HEMATOPOIETIC STEM CELL
        • NEURAL STEM CELL
        • UMBILICAL CORD STEM CELL
        • MESENCHYMAL STEM CELL
        • DENTAL STEM CELL
      • HUMAN EMBRYONIC STEM CELL
      • PLURIPOTENT
      • MOUSE/RAT NEURAL
    3. MARKET BY TECHNOLOGY
      • CELL ACQUISITION
        • BONE MARROW HARVEST
        • UMBILICAL CORD
        • APHERESIS
      • CELL PRODUCTION
        • THERAPEUTIC CLONING
        • IN VITRO FERTILIZATION (IVF)
        • CELL CULTURE
        • ISOLATION
      • CRYOPRESERVATION
      • EXPANSION & SUB-CULTURE
    4. MARKET BY APPLICATION
      • REGENERATIVE MEDICINE
      • DRUG DISCOVERY AND DEVELOPMENT
    5. MARKET BY TREATMENT TYPE
      • ALLOGENEIC STEM CELL THERAPY
      • AUTOLOGIC STEM CELL THERAPY
      • SYNGENEIC STEM CELL THERAPY

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type